• Join
  • Login
  • Contact

Search abstracts

Consequences of involuntary dose reductions during shortage of agalsidase beta - lessons learned from patients suffering from Fabry disease

  • At: Bangkok (Thailand) (2014)
  • Type: Presentation
  • By: LINTHORST, Gabor (Academic Medical Center, Endocrinology and metabolism, Amsterdam, Netherlands)
  • Co-author(s): Smid, Bouwien (Academic Medical Center, Amsterdam, Netherlands)
    Hollak, Carla (Academic Medical Center, Amsterdam, Netherlands)
  • Abstract:

    Background: Treatment with biweekly infusions with alpha-Galactosidase A (aGal A) is the only specific treatment for Fabry disease (aGal A deficiency), using either agalsidase alfa 0,2mg/kg/2wks or agalsidase beta 1,0 mg/kg/2wks (authorized in the EU)). In 2009 due to a viral contamination in the agalsidase beta production facility, a worldwide


  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login
Last update 4 October 2019

FIP Congresses